Lipid News

What’s in your dimer?

William L. Smith
By William L. Smith
August 01, 2015

The term “homodimer” — shorthand for “sequence homodimer” — connotes a protein molecule composed of two monomers with identical primary structures. It often is assumed these proteins function as pairs of independently operating monomers, but there are other scenarios. Many homodimers show a substrate or cofactor binding with high affinity to only half of the seemingly available sites and behave as conformational heterodimers. This permits allosteric regulation that is not possible with true conformational homodimers.

Fig. 1. The cyclooxygenase (COX) and peroxidase (POX) reactions catalyzed by prostaglandin endoperoxide H synthases (PGHSs). There are two isoforms that are commonly known as cyclooxygenases-1 and -2 (COX-1 and COX-2).

 

Prostaglandin endoperoxide H synthases are homodimers that function as conformational heterodimers. These enzymes, commonly known as cyclooxygenases, or COXs for short, catalyze the committed step in prostaglandin synthesis — the conversion of arachidonic acid to prostoglandin H2 (Fig. 1). There is a constitutive COX-1 and an inducible COX-2. These enzymes are composed of catalytic (Ecat) and allosteric (Eallo) monomers (Fig. 2). With COX-2 at least, Ecat and Eallo each remain fixed in the same form during the biologic lifetime of the dimer. Ecat binds heme more avidly than Eallo, and as originally observed by Richard J. Kulmacz and coworkers, maximal COX activity requires only one heme per dimer (See Kulmacz, R.J. & Lands, W. E. and Dong, L., et al).

COXs are regulated by fatty acid tone — the cellular composition and concentration of free fatty acids. Different free fatty acids bind with different affinities to Ecat and Eallo (See Dong, L., et al and Kundalkar, S. N., et al). Free fatty acids binding to Eallo regulates the catalytic efficiency of Ecat. In general, the most common free fatty acids including palmitate and stearate and oleate inhibit COX-1. In contrast, palmitate is relatively specific for stimulating COX-2. Overall, high ratios of common free fatty acids to arachidonic acid, and low concentrations of arachidonic acid, activate COX-2 while suppressing COX-1. COX-1 and COX-2 are also differently affected by the omega-3 fish oil free fatty acids. For example, eicosapentaenoic acid inhibits COX-1 but not COX-2. The molecular basis for the differences in these free fatty acids effects remain to be resolved.

The two COX isoforms are sequence homodimers that function as conformational heterodimers. Both enzymes appear as structurally symmetric homodimers in crystal structures but function in solution as conformational heterodimers composed of an allosteric (Eallo) and a catalytic (Ecat) subunit. The subunits of COX-1 and COX-2 differ in their affinities for ligands and in their responses to ligands. Substrates are in blue. Ligands shown in green stimulate COX activity, and those shown in red inhibit activity

Interest in COXs as drug targets highlights their importance. For example, low-dose aspirin targets platelet COX-1 (See Patrono, C., et al and Grosser, T., et al). Aspirin, naproxen (ALEVE®), and ibuprofen (Motrin®) are mixed COX-1 and COX-2 inhibitors called nonsteroidal anti-inflammatory drugs, which relieve pain by targeting COX-2. Celecoxib (Celebrex®) is a coxib – an NSAID more specific for COX-2. Mechanistically, most NSAIDs and coxibs bind more tightly to Ecat than Eallo. Naproxen is unusual in being a direct competitive inhibitor of COX-1, but an allosteric inhibitor of COX-2 (See Dong, L., et al and Duggan, K. C., et al). As a consequence, naproxen can inhibit 100 percent of COX-1 activity but only 70 percent of COX-2 activity. This may explain why naproxen has limited adverse cardiovascular side effects compared with other COX inhibitors.

There is much more to be learned about these COXs including identification of likely dietary influences on these enzymes. Additionally, differences in cellular fatty acid tone may well contribute to adverse effects of COX inhibitors, thereby impacting therapies. Understanding the structure, chemistry and regulation of these enzymes remains an exciting area of investigation.

William L. Smith
William L. Smith

William Smith is a professor emeritus at the University of Michigan Medical School and a former associate editor of the ASBMB's Journal of Biological Chemistry. In 2006, he won the society's William C. Rose Award.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

A small army of researchers races to build a coronavirus interactome
News

A small army of researchers races to build a coronavirus interactome

April 01, 2020

Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.

Parkinson's  Awareness Month
Health Observance

Parkinson's Awareness Month

April 01, 2020

It is the second-most common progressive neurodegenerative disease, occurring in 1% of people over the age of 60 and in 5% of people over 85.

Multiomics meets antimalarials
Journal News

Multiomics meets antimalarials

March 31, 2020

Researchers in Australia use an innovative multiomics approach to analyze a new drug against malaria parasites.

From the journals: JLR
Journal News

From the journals: JLR

March 31, 2020

Topics include the role of HDL and Smo in inhibiting beta-cell apoptosis, lipid asymmetry in a plasma membrane and apolipoproteins and dementia risk.

Researchers retool genomics labs to provide COVID-19 testing
News

Researchers retool genomics labs to provide COVID-19 testing

March 30, 2020

The pipetting robots are already in place, but that doesn’t make it easy. Here's how academic laboratories are quickly pivoting to provide testing for the coronavirus.

Research on a budget
Essay

Research on a budget

March 30, 2020

As a professor at a small university, Peter Lyons has developed ways of reaching his research goals with limited funding, and he shares some of them here.